A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers

Conclusions ASG-5ME treatment was generally well tolerated with limited evidence of antitumor activity.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research